Incyte Corporation
03/06/2026 | Press release | Distributed by Public on 03/06/2026 16:04
Material Event (Form 8-K)
Item 8.01 Other Events.
On February 27, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") for the supplemental Biologics License Application ("sBLA") for Zynyz® (retifanlimab-dlwr) injection (375mg) for an additional indication for the treatment of adult patients with metastatic non-small cell lung cancer ("NSCLC") in combination with platinum-based chemotherapy. The sBLA was supported by positive efficacy and safety data from the Phase 3 POD1UM-304 trial announced in December 2024.
The CRL cited inspection findings (not specific to Zynyz) at Catalent Indiana, LLC ("Catalent Indiana"), part of Novo Nordisk, the third-party fill-finish facility referenced in the sBLA. The CRL cited the regulatory compliance of Catalent Indiana as the sole approvability issue, and did not cite other approvability concerns, including Zynyz's efficacy and safety data in NSCLC or the third-party drug substance manufacturer.
Incyte Corporation is working closely with the FDA and Catalent Indiana to address the CRL and support a potential sBLA resubmission of Zynyz in NSCLC.
2
Incyte Corporation published this content on March 06, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 06, 2026 at 22:04 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]